These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 3454664)

  • 1. Synthesis and hormonal activity of [Tyr22] glucagon and [desHis1, Tyr22] glucagon.
    Lu GS; Mojsov S; Merrifield RB
    Int J Pept Protein Res; 1987 Apr; 29(4):545-57. PubMed ID: 3454664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity studies of hydrophobic amino acid replacements at positions 9, 11 and 16 of glucagon.
    Sturm NS; Hutzler AM; David CS; Azizeh BY; Trivedi D; Hruby VJ
    J Pept Res; 1997 Apr; 49(4):293-9. PubMed ID: 9176812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-acting thyroid stimulator on thyrotropin stimulation of adenyl cyclase activity in thyroid plasma membranes.
    Yamashita K; Field JB
    J Clin Invest; 1972 Mar; 51(3):463-72. PubMed ID: 4110896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of glucagon antagonists by random molecular mutagenesis and screening.
    Smith RA; Sisk R; Lockhart P; Mathewes S; Gilbert T; Walker K; Piggot J
    Mol Pharmacol; 1993 May; 43(5):741-8. PubMed ID: 8502231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational considerations in the design of glucagon agonists and antagonists: examination using synthetic analogs.
    Hruby VJ; Krstenansky J; Gysin B; Pelton JT; Trivedi D; Mckee RL
    Biopolymers; 1986; 25 Suppl():S135-55. PubMed ID: 3022837
    [No Abstract]   [Full Text] [Related]  

  • 8. Importance of the C-terminal alpha-helical structure for glucagon's biological activity.
    Krstenansky JL; Zechel C; Trivedi D; Hruby VJ
    Int J Pept Protein Res; 1988 Dec; 32(6):468-75. PubMed ID: 2854536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of glucagon partial agonists and antagonists.
    Gysin B; Trivedi D; Johnson DG; Hruby VJ
    Biochemistry; 1986 Dec; 25(25):8278-84. PubMed ID: 3814583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase in stimulatory G protein and glucagon-responsive adenylate cyclase activity in rat liver following partial hepatectomy.
    Yagami T
    Biochem Mol Biol Int; 1994 Jan; 32(1):159-66. PubMed ID: 8012281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of halothane on rat liver adenylate cyclase: role of cytosol components.
    Bernstein KJ; Verosky M; Triner L
    Anesth Analg; 1985 May; 64(5):531-7. PubMed ID: 3994014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total synthesis of crystalline glucagon by the method of solid phase condensation of fragments. Protein Synthesis Group, Shanghai Institute of Biochemistry, Academia Sinica.
    Sci Sin; 1975; 18(6):745-68. PubMed ID: 1224198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity.
    Sturm NS; Lin Y; Burley SK; Krstenansky JL; Ahn JM; Azizeh BY; Trivedi D; Hruby VJ
    J Med Chem; 1998 Jul; 41(15):2693-700. PubMed ID: 9667960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of histidine-1 in glucagon action.
    Unson CG; Macdonald D; Merrifield RB
    Arch Biochem Biophys; 1993 Feb; 300(2):747-50. PubMed ID: 8382034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective effects of charged local anaesthetics on the glucagon- and fluoride-stimulated adenylate cyclase activity of rat-liver plasma membranes.
    Gordon LM; Dipple I; Sauerheber RD; Esgate JA; Houslay MD
    J Supramol Struct; 1980; 14(1):21-32. PubMed ID: 7218799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
    Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
    Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
    Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
    J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.
    Andreu D; Merrifield RB
    Eur J Biochem; 1987 May; 164(3):585-90. PubMed ID: 3032623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational and biological properties of di[delta-(5-nitro-2-pyrimidyl)ornithine 17,18]glucagon. Role of the arginine residues.
    Epand RM; Liepnieks JJ
    J Biol Chem; 1983 Jan; 258(1):203-7. PubMed ID: 6294099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relation of predicted structure to observed conformation and activity of glucagon analogs containing replacements at positions 19, 22, and 23.
    Murphy J; Zhang WJ; Macaulay W; Fasman G; Merrifield RB
    J Biol Chem; 1987 Dec; 262(36):17304-12. PubMed ID: 3693354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.